Share

|

|

|

>

  • Showcases
  • >
  • Support for onasemnogene abeparvovec in older SMA patients

Support for onasemnogene abeparvovec in older SMA patients

Laurent Servais discusses real-world research suggesting that onasemnogene abeparvovec is beneficial in spinal muscular atrophy patients aged 6 months and older, supporting the results of clinical trials involving younger patients (4:13).

Don’t fall behind!

Get the latest headlines – in your specialties of choice – delivered straight to your inbox.

Showcase

MEET THE SENIOR TEAM

Lucy Piper

medwireNews Bureau Chief

Related Showcases

|